摘要
目的探讨莫西沙星与头孢哌酮舒巴坦联用对临床常见耐药菌的抗菌效果。方法采用Vitek-32型全自动细菌鉴定仪,测定莫西沙星与头孢哌酮舒巴坦单用和联用分别对60株金黄色葡萄球菌、大肠埃希菌(ATCC25922)、铜绿假单胞菌、肺炎克雷伯菌和30株粪肠球菌、大肠埃希菌(ATCC35218)、阴沟肠杆菌及幽门螺杆菌的最低抑菌浓度(MIC),并计算联合药敏指数(FIC值)。结果两药联用对临床分离的360株常见耐药致病菌的MIC均明显降低且抗菌作用增强,对金黄色葡萄球菌、粪肠球菌和幽门螺杆菌的体外抗菌作用为协同作用,对大肠埃希菌(ATCC25922)、铜绿假单胞菌、肺炎克雷伯菌、大肠埃希菌(ATCC35218)和阴沟肠杆菌均为相加作用。结论研究结果对指导医院常见耐药菌感染的治疗具有重要意义。
Objective To discuss the antibacterial effects of moxifloxacin（MFX） combined cefoperazone/sulbactam（CPZ/SBT） against clinical common drug-resistance bacteria.Methods The minimal inhibitory concentration（MIC） of MFX and CPZ/SBT alone or in combination against 60 strains of Staphylococcus aureus,Escherichia coli（ATCC 25922）,Pseudomonas aeruginosas and Klebsiella pneumoniae,and 30 strains of Enterococcus faecalis,Escherichia coli（ATCC 35218）,Enterobacter cloacae and Helicobacter pylori were detected respectively by Vitek-32 full automated bact erium detection device and the fractional inhibitory concentration（FIC） index was calculated according to MIC values.Results MIC of two antibiotics combination against 360 strains of common drug-resistance pathogenic bacteria isolated from clinic was reduced significantly and the antibacterial effects were increased.Their antibacterial action in vitro was characterized by synergism action to Stap hylococcus aureus,Enterococcus faecalis and Helicobacter pylori,and additive action to Escherichia cali（ATCC 25922）,Pseudomonas aeruginosas,Klebsiella pneumonia e,Escherichia coli（ATCC 35218） and Enterobacter cloacae.Conclusion The study results may be important to guide the treatment of hospital common drug-resistance bacterial infection.
出处
《中国药业》
CAS
2010年第23期12-13,共2页
China Pharmaceuticals
